Numerous patients cannot afford the medicines that could treat their cancer, autoimmune disorders, and chronic diseases. Regulators can change that by eliminating redundant biosimilar trials when rigorous scientific evidence already establishes similarity. Every unnecessary study adds costs, delays competition, and keeps life-saving medicines beyond patients’ reach.
This is no longer merely a pharmaceutical policy debate. It is a test of whether our regulatory systems serve patients or protect the status quo. Biologic medicines, produced using living systems, have transformed modern medicine.
Food and Drug Administration (FDA) defines biosimilars as highly similar to approved biologic medicines, with no clinically meaningful differences in safety, purity, and potency. They can offer more affordable treatment options, although lower prices are not guaranteed. Yet development remains expensive, and access is deeply unequal.
If roughly one-third of the global population lacks regular access to essential medicines, as reported by the World Health Organization (WHO), access to advanced biologic treatments is an even greater challenge. Even in wealthy countries, uninsured and underinsured patients face impossible choices between treatment and financial survival. The science has advanced.
Regulation must catch up. In March, the FDA announced draft recommendations to streamline certain pharmacokinetic (PK) testing requirements, estimating potential savings of up to 50 percent in study costs, or approximately $20 million. This followed its October 2025 draft guidance recommending that comparative efficacy studies may be unnecessary when other evidence adequately establishes biosimilarity.
These are important steps, but they must become part of a broader international commitment to evidence-based regulation. According to the FDA, biologics accounted for 51 percent of U.S. drug spending in 2024 despite representing just 5 percent of prescriptions. That announcement is a signal, but draft guidance is not enough.
Extract — continue reading at the source.
